Sign in
Virtual Congress
BeiGeneius Webinars
BeiGeneius Resources
About us
beigenemedical.info
Sort by:
Most recent
Oldest
Popular now
Most viewed
Filter by:
Indication
B cell malignancies
Chronic Lymphocytic Leukemia
Classic Hodgkin’s Lymphoma
COVID19
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Cell Lung Cancer
Small Lymphocytic Lymphoma
Waldenström’s Macroglobulinemia
Cancer type
Hematoligical malignancies
Clinical trial
ALPINE
ASPEN
Drug
Zanubrutinib
Author
Alessandra Tedeschi
BeiGene
Christian Buske
Federico Pea
Joe-Elie Salem
Meletios Dimopoulos
Michael Lunn
Paolo Ghia
Ramón García-Sanz
Roger Owen
Véronique Leblond
Wojciech Jurczak
Date
2020
2021
2022
Keywords
ASH
BeiGene
BTKi
Clinical presentation
Clinical trials
CLL
Debate
Diagnosis
DLBCL
FL
Genotype
MCL
Morphology
MZL
Phenotype
Q&A
SLL
Treatment
Waldenström
WM
Type
pdf
video
Reset filter
BeiGeneius Resources
Search results for all Resources:
video
00:12:21
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Mantle cell lymphoma
video
1:29:40
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments
video
00:12:22
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Aggressive lymphomas
video
00:13:33
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - CLL/SLL
video
00:13:48
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Indolent lymphomas
video
00:32:56
03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Q&A
video
1:28:45
10/2021
BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
09/2021
Relapsed/refractory Waldenström's macroglobulinaemia: Key considerations for managing pre-treated patients
pdf
09/2021
BeiGeneius webinar #6 Save the Date
video
1:35:06
08/2021
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations
pdf
07/2021
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations - Agenda
video
00:22:21
07/2021
What are the diagnostic considerations and clinical features for patients presenting with Waldenström’s macroglobulinemia symptoms?
video
00:03:49
07/2021
What is Waldenström’s macroglobulinemia?
video
00:03:33
07/2021
Waldenström’s macroglobulinemia cell morphology
video
00:01:13
07/2021
The Waldenström’s macroglobulinemia-specific immunophenotype
video
00:04:07
07/2021
The implication of genotypes in Waldenström’s macroglobulinemia
video
00:01:25
07/2021
Is it Waldenström’s macroglobulinemia, MGUS or IgM myeloma?
video
00:01:27
07/2021
Key diagnostic assessments when considering Waldenström’s macroglobulinemia
video
00:00:37
07/2021
Summary
video
00:20:36
07/2021
Case study Diagnosing Waldenström’s macroglobulinemia: A patient’s journey
video
00:16:11
07/2021
Debate Should all patients undergo mutation analysis of MYD88 and CXCR4 as part of the Waldenström’s macroglobulinemia diagnostic work up?
video
00:17:32
07/2021
Q&A What challenges do we face in diagnosing Waldenström’s macroglobulinemia?
video
00:01:35
07/2021
Q&A When you have a high-quality bone marrow aspirate, is a bone marrow biopsy necessary for diagnosis?
video
00:02:45
07/2021
Q&A How do you differentiate marginal zone lymphoma with IgM versus Waldenström’s macroglobulinemia?
video
00:02:21
07/2021
Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
video
00:02:18
07/2021
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
07/2021
Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?
video
00:01:15
07/2021
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
video
00:01:10
07/2021
Q&A Would you deny BTK inhibitor therapy to a Waldenström’s macroglobulinemia patient who is wild-type for MYD88 and CXCR4 genes?
video
00:02:03
07/2021
Q&A Does Waldenström’s macroglobulinemia exist in association with production of immunoglobulins other than IgM, such as IgG or IgA? How are these patients treated?
video
00:01:08
07/2021
Q&A Do you look at serum free light chain levels if there is amyloid in the bone marrow biopsy?
pdf
07/2021
BeiGeneius Steering Committe biographies
pdf
07/2021
BeiGeneius webinars 1+2, Q&A
pdf
07/2021
BeiGeneius Bulletin Issue 2
pdf
07/2021
BeiGeneius Bulletin Issue 3
pdf
07/2021
BeiGeneius webinar #4 Save the Date
pdf
07/2021
BeiGeneius webinar 4 invitation letter
pdf
07/2021
BeiGeneius webinar #3 Q&A
video
21:29
05/2021
Multidisciplinary management of Waldenström’s macroglobulinemia: The hematologist’s perspective
video
22:36
05/2021
Diagnosis and management of peripheral neuropathies in Waldenström’s macroglobulinemia and related IgM disorders
video
23:37
05/2021
Cardiovascular toxicities associated with BTK inhibitors: A case study and review
video
24:55
05/2021
Discussion and audience Q&A
video
01:38:08
05/2021
BeiGeneius - Multidisciplinary management of Waldenström’s macroglobulinemia: Providing specialist care beyond hematology
video
01:25:28
03/2021
BeiGeneius - Relapsed/refractory Waldenström’s macroglobulinemia: Key considerations for managing pre-treated patients
video
01:21:00
01/2021
BeiGeneius - Initiation of treatment for Waldenström’s macroglobulinemia: Practical guidance for starting treatment and managing complications
video
01:31:49
11/2020
Challenges in the diagnosis, staging, and clinical work up of Waldenström’s macroglobulinemia (WM): A practical guide to current best practice The complete webcast.
Welcome to the BeiGene EU Medical Information Website
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit
beigene.com
for more information.
I am a Healthcare Professional from:
I am not a healthcare professional
×
You are now leaving the website of BeiGene Europe (beigenemedical.info)
Important notice
This link is provided for information purposes only. Please be aware that, if you click on it, you will leave the BeiGene Europe website, which is directed exclusively at users in Europe. The link will take you to a website owned and operated by an independent party over which BeiGene has no control or influence (“third-party website”).
BeiGene Europe makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene declines any responsibility for third-party information. BeiGene makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the target group of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.
Do you really want to leave the website of BeiGene Europe?
×
You are now leaving the italian website of BeiGene EU.
You are now leaving the italian website of BeiGene EU.
Please check your webbrowser
We noticed that your webrowser doesn't meet the requirements, please upgrade!
OK